Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Cardiology / Cardiovascular
A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries
What is being tested: Lanadelumab, a monoclonal antibody targeting plasma kallikrein, is being evaluated as a preventative treatment for hereditary angioedema (HAE) in the…
05 May 2026 NCT07251933
● Recruiting Phase II Cardiology / Cardiovascular
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
What is being tested: RLY-2608, a mutant-selective PI3Kα inhibitor, is being evaluated for safety and efficacy in treating PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-driven…
05 May 2026 NCT06789913
● Recruiting Phase III Cardiology / Cardiovascular
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
What is being tested: Omecamtiv mecarbil (CK-1827452), an investigational cardiac myosin activator, is being evaluated to determine if it reduces adverse outcomes including hospitalisation,…
05 May 2026 NCT06736574
● Recruiting Cardiology / Cardiovascular
Evaluation of A Clinical Diagnostic Test for CRDS
Test being evaluated: A novel clinical diagnostic test for Calcium Release Deficiency Syndrome (CRDS) caused by RyR2 loss-of-function mutations, designed to replace current cellular-based…
05 May 2026 NCT06188689
● Recruiting Phase I Oncology
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
What is being tested: AZD9574 is being evaluated as both a standalone treatment and in combination with established anti-cancer agents, with assessment of safety,…
05 May 2026 NCT05417594
● Recruiting Phase III Oncology
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
What is being tested: ALLTogether is a master protocol that consolidates evidence-based treatment approaches for acute lymphoblastic leukaemia (ALL) across infants, children, and young…
05 May 2026 NCT04307576
active not recruiting Phase III
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Monthly eye injections of vonaprument tested to slow vision loss in dry age-related macular degeneration with geographic atrophy.
04 May 2026 NCT06510816
● Recruiting Phase III Gastroenterology
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
A new drug called Afimkibart is being tested to see if it safely treats moderate to severe ulcerative colitis better than placebo.
04 May 2026 NCT06588855
active not recruiting Phase III
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
Two-year trial testing EYP-1901 against aflibercept for wet age-related macular degeneration, with main results at one year.
04 May 2026 NCT06683742
● Recruiting Phase III Gastroenterology
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn’s Disease
New drug afimkibart tested for safely treating moderate-to-severe Crohn's disease in a phase three trial comparing it against placebo.
04 May 2026 NCT06819878
● Recruiting Mental Health / Psychiatry
Post Intensive Care Accelerometery to Study and Support Recovery Outcomes
Wrist activity monitors track ICU patients' recovery at home to identify problems early and guide support.
04 May 2026 NCT07466446
active not recruiting Phase III
Oral N-acetylcysteine for Retinitis Pigmentosa
NAC supplement may slow vision loss in retinitis pigmentosa by reducing oxidative stress; ongoing trials testing long-term effectiveness.
04 May 2026 NCT05537220
active not recruiting Oncology
Measuring and Mapping Cognitive Decline After Brain Radiosurgery
Study tests whether brain radiosurgery for tumours damages thinking ability and identifies brain areas at risk to spare during future treatment.
04 May 2026 NCT06466720
● Recruiting Phase III
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Rilzabrutinib reduces disease flares and controls IgG4-related disease activity better than placebo over 52 weeks in adults.
04 May 2026 NCT07190196
● Recruiting Cardiology / Cardiovascular
Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart
What is being tested: This trial compares three catheter ablation techniques (cryoballoon, radiofrequency, and pulsed field ablation) against standard medical management (rate control and…
04 May 2026 NCT06505798
● Recruiting Infectious Disease
CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure
What is being tested: CERAMENT G (an antibiotic-loaded bone void filler) is being evaluated as part of single-stage surgical treatment for osteomyelitis, combining debridement…
04 May 2026 NCT06555848
● Recruiting Phase II Respiratory / COPD / Asthma
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Treatment being tested: PF-07275315, an investigational medicine for moderate-to-severe asthma, with assessment of its safety profile and clinical efficacy in reducing breathing difficulties. Patient…
04 May 2026 NCT06977581
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
What is being tested: The efficacy and safety of axatilimab (a CD40 ligand antagonist) combined with corticosteroids versus placebo plus corticosteroids as first-line treatment…
04 May 2026 NCT06585774
● Recruiting Cardiology / Cardiovascular
Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health
What is being tested: The acute effects of whey protein-enriched milk fat globule membrane (MFGM) supplementation added to a high-fat meal on postprandial cardiovascular…
04 May 2026 NCT06953232
● Recruiting Phase II Cardiology / Cardiovascular
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
RP-A501 is a gene therapy using AAV9 vector to deliver the LAMP2B gene – designed to address the underlying genetic defect in Danon disease…
04 May 2026 NCT06092034
● Recruiting Phase III Oncology
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
What is being tested: Revumenib, a menin inhibitor, combined with intensive chemotherapy versus chemotherapy alone in newly diagnosed AML patients with NPM1 mutations, evaluating…
04 May 2026 NCT07211958
● Recruiting Phase I Oncology
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
What is being tested: GDC-7035, a novel investigational agent, is undergoing first-in-human evaluation for safety, pharmacokinetics, and anti-cancer activity both as monotherapy and in…
04 May 2026 NCT06619587
● Recruiting Phase I Oncology
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Novel therapeutic being tested: IDRX-42 is a first-in-human investigational agent being evaluated for safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with advanced…
04 May 2026 NCT05489237
● Recruiting Phase I Oncology
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
What is being tested: TGX-007, an AAV-mediated dual-payload gene therapy delivered directly into brain tumours to establish safety, optimal biological dose, and efficacy in…
04 May 2026 NCT07346144
● Recruiting Diabetes / Metabolic
Assessing the Dose-response of Muscle Protein Synthesis to “Super-whey” in Older Adults
One-sentence summary: This study tests three doses of leucine-enriched whey protein to find which best stimulates muscle building in older people.
01 May 2026 NCT05700058
● Recruiting Phase III Rheumatology
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Dapirolizumab pegol added to standard treatment improves moderate to severe lupus disease activity.
01 May 2026 NCT06617325
● Recruiting Gastroenterology
Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young
Study tests whether personalised approaches help young adults swap red meat for fish or plants, improving health markers.
01 May 2026 NCT06714656
● Recruiting Gastroenterology
Fast Food Online Delivery Purchase Behaviour in the Presence and Absence of Price-based Incentives
Removing price discounts from fast food delivery apps slightly reduced calorie selections, but effects were unclear and based on hypothetical choices only.
01 May 2026 NCT07368881
active not recruiting Phase III Oncology
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Adding pembrolizumab immunotherapy to chemoradiotherapy improves survival and delays cancer progression in muscle-invasive bladder cancer patients avoiding surgery.
01 May 2026 NCT04241185
active not recruiting Phase III Gastroenterology
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Elafibranor tested against placebo in PBC patients inadequately responding to ursodeoxycholic acid, assessing alkaline phosphatase reduction and safety.
01 May 2026 NCT04526665
active not recruiting Phase III Oncology
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Two immunotherapy drugs versus standard chemotherapy for advanced lung cancer without specific genetic mutations.
01 May 2026 NCT02542293
active not recruiting Phase III Neurology
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Long-term safety and efficacy study of ocrelizumab, a B-cell depleting antibody, in multiple sclerosis patients continuing from previous trials.
01 May 2026 NCT05269004
● Recruiting
Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants
Long-term safety and performance study of different Prevision hip stem variants in routine clinical practice.
01 May 2026 NCT06626490
active not recruiting Phase III Mental Health / Psychiatry
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
MM120 was tested against placebo for anxiety disorder in a large, rigorous trial with long-term follow-up.
01 May 2026 NCT06809595
● Recruiting Phase I Oncology
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
What is being tested: AZD9750, a novel investigational agent, is being evaluated as monotherapy and in combination with saruparib (a PARP inhibitor) in metastatic…
01 May 2026 NCT07336446
● Recruiting Phase I Neurology
A Study of AZD0120 in Autoimmune Diseases
What is being tested: AZD0120, a dual-targeting CAR+ T-cell therapy that simultaneously targets BCMA and CD19, is being evaluated for safety and tolerability in…
01 May 2026 NCT07295847
● Recruiting Phase II
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
What is being tested: Safety and tolerability of difelikefalin, a novel therapeutic agent, in adolescent patients undergoing haemodialysis who experience moderate-to-severe pruritus (a significant…
01 May 2026 NCT06593392
● Recruiting Phase II Gastroenterology
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
Treatment being tested: ALG-000184, a novel oral antiviral agent administered once daily as monotherapy, compared against the established standard tenofovir disoproxil fumarate (TDF) in…
01 May 2026 NCT06963710
● Recruiting Phase I Cardiology / Cardiovascular
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
What is being tested: FT819, a novel therapeutic agent targeting B-cell activity, is being evaluated for safety, pharmacokinetics, and anti-B-cell efficacy in patients with…
01 May 2026 NCT06308978
● Recruiting Cardiology / Cardiovascular
The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field
What is being tested: Development and clinical validation of a custom-built cardiac coil designed specifically for a whole-body Field-Cycling MRI (FFC-MRI) prototype to enable…
01 May 2026 NCT04458883
● Recruiting Phase II Cardiology / Cardiovascular
Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction
What is being tested: This trial evaluates whether coronary artery stent placement improves outcomes in patients with HFpEF who have concurrent coronary artery disease,…
01 May 2026 NCT07560436
● Recruiting Cardiology / Cardiovascular
Multicentre Hypertrophic Cardiomyopathy Registry
What is being tested: A multicentre registry collecting comprehensive clinical data on hypertrophic cardiomyopathy patients to understand disease progression, phenotypes, and outcomes across diverse…
01 May 2026 NCT07381894
● Recruiting Phase I Oncology
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
What is being tested: The SpectraCure P18 System combined with verteporfin (a photosensitizer) is being evaluated for safety, efficacy, and optimal dosing parameters in…
01 May 2026 NCT03067051
● Recruiting Phase II Oncology
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Drug and target: Lirafugratinib, a selective FGFR2 inhibitor, is being tested in previously treated patients with advanced/metastatic solid tumours (excluding cholangiocarcinoma) that harbour FGFR2…
01 May 2026 NCT07359820
● Recruiting Phase II Oncology
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
What is being tested: ASP5541, a novel androgen receptor pathway inhibitor (ARPI), is being evaluated in a Phase 2 study as a potential treatment…
01 May 2026 NCT07005154
active not recruiting Phase III Gastroenterology
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Trial testing elafibranor versus placebo in primary biliary cholangitis patients who cannot tolerate or inadequately respond to ursodeoxycholic acid, measuring effects on alkaline phosphatase…
30 Apr 2026 NCT06383403
active not recruiting Phase III
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Two new PNH drugs (pozelimab + cemdisiran) tested for safety and effectiveness against existing complement inhibitor treatments.
30 Apr 2026 NCT05133531
active not recruiting
ADH1 and ADH2 Disease Monitoring Study (DMS)
Study tracking how autosomal dominant hypocalcaemia types 1 and 2 develop and progress over time using patient medical records.
30 Apr 2026 NCT05227287
● Recruiting Phase I Dermatology
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Early-stage trial testing new drug SYX-5219 for safety and effectiveness in healthy people and atopic dermatitis patients.
30 Apr 2026 NCT07558668
● Recruiting
Diagnostic Accuracy of Oral Images, OPGs, Biomarkers and Questionnaires vs. Clinical Assessment for Periodontal Disease (PostNCT07164573)
Study tests whether photos, scans, saliva tests and questionnaires can accurately detect gum disease compared to clinical examination.
30 Apr 2026 NCT07406867